CRISPR Therapeutics(CRSP) Benzinga·2025-05-07 18:17Core Insights - CRISPR Therapeutics AG reported topline results from a Phase 1 trial for CTX310, targeting ANGPTL3 to address atherosclerotic heart disease risk factors [1][4] - The trial involved 10 patients across four cohorts, showing dose-dependent reductions in ANGPTL3, triglycerides (TGs), and low-density lipoprotein (LDL) [2][9] - CTX310 demonstrated a favorable safety profile with no severe adverse events reported [3] Trial Details - The trial included lean body weight-based doses of DL1 (0.1 mg/kg), DL2 (0.3 mg/kg), DL3 (0.6 mg/kg), and DL4 (0.8 mg/kg) with at least 30 days of follow-up for each participant [2] - A DL4 patient experienced an 82% reduction in triglycerides from a baseline of 1073 mg/dL, while a DL3 patient had an 81% reduction in LDL-C from a baseline of 256 mg/dL [9] Financials and Market Response - As of March 31, CRISPR reported cash, cash equivalents, and marketable securities totaling 34.15 [7] Analyst Commentary - Chardan Research lowered the price target for CRISPR from 82, maintaining a Buy rating, indicating that while the topline results show safety and activity, further data in 2H25 will be crucial for assessing competitiveness [4][5] - The topline readout did not include patient-level data, which may introduce variability, but biomarker results align with benchmarks set by RNAi assets for ANGPTL3 [5]